Assess whether a CMO finding is a delay or a refuse-to-file risk (96d101)

Situation

In a 505(b)(2) program relying on literature plus a bridging study, biosimilar analytical similarity report is the evidence after a CMO 483 that maps to the NDA CMC module. Labeling negotiator has to pick A CMO finding is a delay or A refuse-to-file risk for this Pharma & Life Sciences CMC and Development Pathways close using biosimilar analytical similarity report.

Decision

Labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study must choose A CMO finding is a delay / A refuse-to-file risk using biosimilar analytical similarity report after a CMO 483 that maps to the NDA CMC module.

Hypotheses to test

• The population in biosimilar analytical similarity report is the one a CMO 483 that maps to the NDA CMC module named, so A CMO finding is a delay follows for this CMC and Development Pathways file.
• The population in biosimilar analytical similarity report is adjacent only to a CMO 483 that maps to the NDA CMC module; A refuse-to-file risk is the honest Pharma & Life Sciences call.
• A 505(b)(2) program relying on literature plus a bridging study already contained a CMO 483 that maps to the NDA CMC module before biosimilar analytical similarity report arrived; no new CMC and Development Pathways path.
• Provenance on biosimilar analytical similarity report after a CMO 483 that maps to the NDA CMC module is broken; do not pick A CMO finding is a delay or A refuse-to-file risk yet.

Analysis required

• Check whether biosimilar analytical similarity report supports the labeled claim labeling negotiator would keep.
• Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study.
• Trace CMC, labeling, or pharmacovigilance facts in biosimilar analytical similarity report after a CMO 483 that maps to the NDA CMC module.
• For this Pharma & Life Sciences CMC and Development Pathways file, read biosimilar analytical similarity report against a CMO 483 that maps to the NDA CMC module and write the one fact that would move a CMO finding is for labeling negotiator.

Recommendation

Choose A CMO finding is a delay / A refuse-to-file risk on this Pharma & Life Sciences / CMC and Development Pathways packet (biosimilar analytical similarity report after a CMO 483 that maps to the NDA CMC module). Lead with the Pharma & Life Sciences option biosimilar analytical similarity report can support after a CMO 483 that maps to the NDA CMC module, then the two facts that force it, then the Monday action for labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study.